1 of STAT3 and its inhibitors, including SHP1,
were comparable between 5azaD/TSA and control cultures f
2 sue volume and intramyocellular lipid levels
were comparable between 8-wk fructose- and glucose-fed m
3 udes of induction of host cytokine responses
were comparable between A(H7N9) and H5N1 virus infection
4 Duration of support
was comparable between ACE-I and control subjects (96 +/
5 sicular stomatitis virus single-cycle yields
were comparable between adar1(-/-) and adar2(-/-) cells,
6 ngle-cycle yields and growth kinetics of PyV
were comparable between adar1(-/-) and adar2(-/-) geneti
7 s, the median number of positive lymph nodes
was comparable between ADC and SRC < 50% (4 vs 5, P = 0.
8 f the gp120- and V1V2-specific IgG responses
were comparable between adults and infants immunized wit
9 ne responses to known CD8(+) T cell antigens
was comparable between all strains.
10 ical full-length amyloid-beta42 accumulation
was comparable between Alzheimer's disease and pathologi
11 risk-standardized unplanned hospital visits
were comparable between ambulatory surgery centers and h
12 4(+) T cell depletion, and the onset of AIDS
were comparable between anti-IL-15- and control-treated
13 e-carboplatin; grade 3 to 4 thrombocytopenia
was comparable between arms and anemia was higher in the
14 e of non-VZV-related herpes viral infections
was comparable between arms.
15 sful in avoiding referral bias (participants
were comparable between arms on important characteristic
16 Adverse events
were comparable between arms, except for a lower inciden
17 (88% and 84% in arms B and D, respectively)
were comparable between arms.
18 Tolerability profiles
were comparable between arms.
19 cteristics and mean tacrolimus trough levels
were comparable between arms.
20 Trends
were comparable between assays.
21 Image quality
was comparable between awake and anesthetized conditions
22 On the other hand, expression levels of HA
were comparable between B16-F1 and B16-F10 melanoma cell
23 take of eGFP labelled EVs in recipient cells
was comparable between BE-SEC and UC samples.
24 ient and AD patients, while IL-31 expression
was comparable between both DOCK8-deficient and AD cohor
25 Stress myocardial flow
was comparable between both groups (2.3 +/- 0.9 vs. 2.3
26 eplacement because of infective endocarditis
was comparable between both groups (Melody, 88%; SPVR, 8
27 Results Engraftment
was comparable between both groups.
28 V-MMRV UVV programmes on varicella incidence
was comparable between both VCVs at equilibrium.
29 Neointimal thickness and inflammatory scores
were comparable between both devices at 180 days.
30 rn size, concomitant injuries, and mortality
were comparable between both groups.
31 differences in NFV and regurgitant fraction
were comparable between both methods, NFV variation over
32 However, mean ESV and EDV at stress and rest
were comparable between both subgroups (p = NS).
33 At the same time point, binary restenosis
was comparable between BVS and DES (7.8% versus 8.9%; P=
34 e antisense RAN translation product poly(PR)
is comparable between c9ALS/FTD and SCA36 patient sample
35 Odds ratios
were comparable between Cache County and AlzGene.org whe
36 The prevalence of metabolic syndrome
was comparable between cases (17%) and controls (9%) (P
37 es of CD27(-)CD28(-) cells or CD57(+) cells)
were comparable between cases and controls.
38 gher in cases, CMV-specific T-cell responses
were comparable between cases and controls.
39 lecular pattern (MAMP) content of microbiota
were comparable between CD and HC, but a sub-population
40 madelta-17 and gammadelta-IFNgamma effectors
were comparable between CD28(+/+) and CD28(-/-) mice.
41 Baseline and clinical parameters
were comparable between children receiving LGG and place
42 , CEC-normalized sorption for most compounds
was comparable between clays and soil organic matter.
43 Variant allele fractions
were comparable between clonal ICUS (CCUS) and MDS as we
44 3-CGA concentrations and pH
were comparable between cold and hot brews.
45 Progression of GA area
is comparable between color photographs and FAF images,
46 f NBN and ATM recruited to the sites of DSBs
was comparable between control cells and those expressin
47 Post-HCT scores
were comparable between controls and autologous and redu
48 lasma arginine and citrulline concentrations
were comparable between COPD patients and controls, whol
49 in Finland, although composition of classes
was comparable between countries.
50 Median MBF at rest
was comparable between CZT and PET (0.89 [interquartile
51 Posttransplantation kidney function
is comparable between DCD and DBD kidney transplantation
52 In multicentric disease, outcomes
are comparable between debulking surgery alone, immunoch
53 Frequency of drug-related adverse events
was comparable between deferasirox (35.4%) and deferoxam
54 In contrast, monocyte and DC recruitment
was comparable between DEP-exposed wild-type and CCR5 kn
55 after CTO percutaneous coronary intervention
was comparable between different approaches.
56 cted dose, the levels of gadolinium measured
were comparable between different doses, indicating that
57 he growing leaf, while GRF4 and GRF10 levels
were comparable between division zone and expansion zone
58 Kidney graft survival
is comparable between donation after cardiac death (DCD)
59 S1P-induced Akt and ERK1/2 activation
were comparable between ECs of different in vitro ages;
60 the allelic effects for most of the 10 SNPs
were comparable between Europeans and Asians.
61 Rates of PTMS
were comparable between EVR-containing and TAC control r
62 The VA decline rate
was comparable between eyes with initial noncentral and
63 The central corneal thickness
was comparable between fellow-eye primary and secondary
64 Node-positive primary
was comparable between FOLFOX and 5-FU but lower in the
65 ion, immune recovery and development of ADEs
were comparable between foreign-born and US-born patient
66 to the period of 1978-2015, so that results
are comparable between genera, we detected a significant
67 eletal reorganization, and its TrkB receptor
were comparable between genotypes.
68 s of leading edge protrusion and retraction,
were comparable between genotypes; however, ARPC3(-/-) c
69 though proliferation of isolated fibroblasts
was comparable between GPA and controls, GPA samples sho
70 city, reactogenicity, and safety appeared to
be comparable between groups.
71 mated glomerular filtration rate at month 36
was comparable between groups (68.1 vs 67.3 mL/min/1.73
72 Patient age
was comparable between groups (intervention, 45 years +/
73 The probability of being ready for RTx
was comparable between groups A and B.
74 of adverse remodeling; however, infarct size
was comparable between groups suggesting that the benefi
75 OXPHOS capacity
was comparable between groups when complex I- and comple
76 Freedom from death
was comparable between groups with 1-, 2-, and 5-year su
77 Although LV ejection fraction
was comparable between groups, longitudinal peak was red
78 Whereas whole-body fat mass
was comparable between groups, persons with OLD had incr
79 nsulin levels, endogenous glucose production
was comparable between groups, suggesting lower hepatic
80 Safety generally
was comparable between groups.
81 Except for HNC, health care utilization
was comparable between groups.
82 aled a progressive decrease over time, which
was comparable between groups.
83 diastolic dysfunction; however, infarct size
was comparable between groups.
84 ence of adverse events (AEs) and serious AEs
was comparable between groups.
85 Median time to clearance of the bloodstream
was comparable between groups.
86 Overall, dialysis adequacy
was comparable between groups.
87 Meissner corpuscles and dermal nerve bundles
were comparable between groups (P>0.07).
88 Mechanical and thermal pain thresholds
were comparable between groups (P>0.13).
89 risk (5%).Most recipient and donor features
were comparable between groups A and B.The 1- and 3-year
90 in fractional anisotropy within these tracts
were comparable between groups across the age span.
91 Mean ECD, CV, and %HEX values
were comparable between groups at baseline.
92 ual Analog Scale, and Functional Pain scores
were comparable between groups over time.
93 Bowel screening examinations
were comparable between groups throughout.
94 Baseline characteristics
were comparable between groups, including volume of asci
95 Baseline characteristics
were comparable between groups, including volume of asci
96 Rates of HBeAg loss and HBeAg seroconversion
were comparable between groups, whereas the rate of alan
97 on, infection, tissue necrosis, and hematoma
were comparable between groups.
98 Safety parameters
were comparable between groups.
99 complication rates and BPVA after treatment
were comparable between groups.
100 tomach upset and headache, yet dropout rates
were comparable between groups.
101 se events and dropouts due to adverse events
were comparable between groups.
102 g both uncovered and malapposed at follow-up
were comparable between groups.
103 , rates of surgery and moderate-to-severe MR
were comparable between groups.
104 Severity of cirrhosis and platelet count
were comparable between groups.
105 0 days after the last manipulation, LC rates
were comparable between groups.
106 l resistance and incidence of adverse events
were comparable between groups.
107 aling complications and other adverse events
were comparable between groups.
108 ne demographics and clinical characteristics
were comparable between groups.
109 , major infections, and resource utilization
were comparable between groups.
110 luding AKI stage and sepsis-related HRS-AKI,
were comparable between groups.
111 with than without HF; however, overall rates
were comparable between groups.
112 the frequency and severity of adverse events
were comparable between groups.
113 postoperative morbidity and mortality rates
were comparable between groups.
114 Histological findings
were comparable between groups.
115 Adverse events
were comparable between groups; 16.1% of rituximab and 1
116 2 mumol/g vs. 0.6 +/- 0.3 mumol/g; P = 0.52)
were comparable between healthy subjects and T1DM patien
117 arthritic changes associated with knee pain
are comparable between hemiplegic and non-hemiplegic kne
118 ecific superenhancers, and global aneuploidy
were comparable between high- and low-quality lines, abe
119 ses to long-term lamivudine-containing HAART
were comparable between HIV-infected patients with HBV g
120 erstand the extent to which MFC organization
is comparable between humans and animals commonly used i
121 Although Th9 and Th17 levels
are comparable between infected TGF-betaRII DN and wild-
122 Composite 1-year outcome rates
were comparable between IVSR and VSF-trained surgeons fo
123 tage of cells in each round of cell division
are comparable between Jak3-deficent and wild-type T cel
124 els of IL-6, MCP-1, IFN-gamma, and TNF-alpha
were comparable between L. monocytogenes-infected AhR(-/
125 mitted per unit dry weight of plant material
is comparable between laboratory enclosure measurements
126 Potencies and effects
were comparable between LCLs of two genetically unrelate
127 s, changes in QRS area, SDAT, and LVdP/dtmax
were comparable between LVs and HB pacing.
128 an] vs 55 seconds +/- 3, P < .001), and time
was comparable between magnetically assisted and standar
129 While Amh-specific receptor expression
was comparable between males and females, mRNA and prote
130 This homeostatic turnover
was comparable between memory CD8 T cells of different v
131 cy and safety of the potent P2Y12 inhibitors
were comparable between men and women.
132 identification of influenza A virus subtypes
were comparable between methods.
133 hospital stay (mean 17 vs 17 days, P > 0.99)
were comparable between MIPD and OPD.
134 allbladder, pancreas, spleen, and kidney may
be comparable between MR systems from different vendors
135 percentage of oscillating lipid metabolites
was comparable between muscle tissue and cultured myotub
136 Substrate uptake and surface expression
were comparable between mutant and WT SERTs.
137 morphology, photopic vision-guided behaviour
is comparable between normal and cone ERG(absent) RPGRIP
138 Baseline any type HPV prevalence
was comparable between obese and nonobese women (18.7% v
139 Overall safety
was comparable between OH+ (n = 288, 27.5%) and OH- (n =
140 ion, movement is directionally biased, speed
is comparable between origins, and cell growth can accou
141 The conventional HRV parameters
were comparable between PA and EH patients.
142 MS4A1 gene expression levels in PBMC
were comparable between patient groups at all timepoints
143 Outcomes
were comparable between patient groups, and worse than t
144 Outcomes
are comparable between patients with both types after ad
145 Induction of cytokine-induced SH2 protein
was comparable between patients and volunteers, whereas
146 While in-hospital mortality
was comparable between patients with atypical and typica
147 ocleidomastoid and tibialis anterior muscles
were comparable between patients and controls.
148 es for systemically administered antibiotics
were comparable between patients receiving selective dec
149 files and expected operative mortality rates
were comparable between patients who underwent surgery b
150 Rates of SVR
were comparable between patients whose anemia was manage
151 Responses
were comparable between patients with euvolemia and thos
152 Pharmacokinetics
were comparable between patients with sarcoma and those
153 Mean better eye logMAR visual acuity (VA)
was comparable between PCG and secondary childhood glauc
154 sponse frequency (17/26 donors) and strength
were comparable between Phl p 12 and Phl p 1.
155 Plasma IL-6, IL-8, and IL-10 concentrations
were comparable between PICU and floor patients, but hig
156 tranded, double-stranded, and mismatched DNA
were comparable between Pol and Pol2core.
157 Dlx2(+) cells in CGEs
were comparable between preterm and term pups.
158 GluR1-GluR4 expressions
were comparable between preterm humans and rabbits with
159 ion of type-specific and cross-reactive MBCs
were comparable between primary and secondary DENV infec
160 observed after exposure to moderate hypoxia
were comparable between rho0 cells, which lack functiona
161 3; 95% confidence interval, 0.47-1.85) risks
were comparable between rivaroxaban and VKA new users.
162 The incidences of adverse events
were comparable between S/V and enalapril across all 4 s
163 Outcomes
were comparable between sensitized and control recipient
164 .04), whereas the rate of adenoma detection
was comparable between sets.
165 ecreasing BP (i.e. early phase II of the VM)
was comparable between sexes, but it was greater in men
166 blood pressure (BP) distribution (variation)
was comparable between sexes.
167 PAD severity and medical treatment
were comparable between sexes, whereas prior lower extre
168 CRT-related toxicity
was comparable between SGs.
169 ell activation, proliferation, and apoptosis
were comparable between SIVmnd-1- and SIVmnd-2-infected
170 and whole salivary IL-1beta and IL-6 levels
were comparable between smokers and never-smokers.
171 ilation, or in-hospital all-cause mortality)
was comparable between SOTr and controls (40% vs 48%, od
172 Running
was comparable between strains and VWR reduced body weig
173 Enrollment characteristics
were comparable between study groups.
174 ine, small airway function (R5 -R20 and X5 )
was comparable between subjects with asymptomatic BHR an
175 Clinical outcomes
were comparable between TAVR and SAVR across all groups,
176 TFV-DP concentrations at week 4
were comparable between TGW and TGM (mean difference -6%
177 , QOL, functional outcome, and complications
are comparable between the groups.
178 the MRG agonist peptide, BAM15, appeared to
be comparable between the BLA assay and the intracellula
179 d point (death/stroke/myocardial infarction)
is comparable between the 2 treatment options for diabet
180 While population-based variability
is comparable between the routes, FcepsilonRI- and MRGPR
181 risk of patient-oriented composite end point
was comparable between the 2 groups (22.7% versus 22.9%;
182 Mortality
was comparable between the 2 groups (HR, 1.19; 95% CI, 0
183 however the final visual acuity at 6 months
was comparable between the 2 groups.
184 The risk of infection
was comparable between the 2 groups; however, patients w
185 umor growth rate, determined from CT images,
was comparable between the animals with recurrent tumors
186 Overall rate of adverse events (AEs)
was comparable between the ASA404 and placebo arms.
187 Performance
was comparable between the best measures of asymmetry an
188 Cervix visualization
was comparable between the Callascope and speculum (83%
189 on of patients experiencing an adverse event
was comparable between the combined guselkumab (13/20 [6
190 Favorable neurologic outcome at discharge
was comparable between the cyclosporine and control grou
191 e the frequency of medical contraindications
was comparable between the genders.
192 y later time points the extent of activation
was comparable between the glial cell types.
193 The 28-day mortality
was comparable between the groups (21.4%, G-CSF; 28.6%,
194 Isotopic glomerular filtration rate
was comparable between the groups at 1 year (57+/-26 mL/
195 of cartilage damage and joint cyst formation
was comparable between the groups, the degree of ligamen
196 ICU stay
was comparable between the groups.
197 s factor alpha (TNF-alpha)-induced apoptosis
was comparable between the HeLa lines.
198 Although virus shedding
was comparable between the N(752) and D(752) variants, i
199 Meanwhile, CCT
was comparable between the PK and control groups (P = .9
200 requency of CD4+ T cells harboring HIV-1 DNA
was comparable between the sexes, but there was higher c
201 catheter-related bloodstream infection risk
was comparable between the sites.
202 Patient survival
was comparable between the study groups.
203 In five studies, CBL around implants
was comparable between the test and control groups.
204 Using this method, neuronal differentiation
was comparable between the three genotypes of iPSCs.
205 mean transit time and blood volume fraction)
was comparable between the three groups of animals.
206 T and HA whereas the motivation for the drug
was comparable between the three groups.
207 The median duration of POAF
was comparable between the treatment and the control gro
208 The overall response rate
was comparable between the two arms (GO, 45%; no GO, 49%
209 TTP
was comparable between the two arms in treatment-naive p
210 ion and that the magnitude of the modulation
was comparable between the two brain areas.
211 Antibiotic administration at 1 and 3 hours
was comparable between the two cohorts, but initial anti
212 that resulted in study drug discontinuation
was comparable between the two groups.
213 blood blasts (27% v 33%); risk distribution
was comparable between the two groups.
214 Although liver exposure
was comparable between the two mouse strains (despite th
215 ime course of pulmonary markers in survivors
was comparable between the two serogroups.
216 t required intervention after trabeculectomy
were comparable between the 2 groups (DSAEK vs PK, all i
217 Length of stay and total hospital cost
were comparable between the 2 groups (P > .05).
218 Intraoperative complications
were comparable between the 2 groups except the occurren
219 9) and mortality rates (6% vs 4%, P = 0.214)
were comparable between the 2 groups, patients who under
220 erior reattachment rates and PVR recurrence)
were comparable between the 2 groups.
221 Postoperative pain scores
were comparable between the 2 groups.
222 emophilus influenzae type b vaccine antigens
were comparable between the 2 groups.
223 and severity of other adverse drug reactions
were comparable between the 2 groups.
224 P = 0.03), but the 1- and 5-year DCGS rates
were comparable between the 2 groups; moreover, the 1-,
225 roprotection rates, and seroconversion rates
were comparable between the 2 vaccines.
226 omes (procedure, fluoroscopy, and PVI times)
were comparable between the 3 arms.
227 ron, tear film status, and lid abnormalities
were comparable between the 3 groups.
228 nd 2.9+/-1.9 segments, respectively; P=0.77)
were comparable between the 4 approaches.
229 Patient demographics and baseline QOL scores
were comparable between the 74-Gy and 60-Gy arms.
230 Overall, the sensitivity and NPV
were comparable between the assays, but the IHPV assay d
231 fection efficiency in HeLa and NIH/3T3 cells
were comparable between the copolymers but pHCathK(10) w
232 Rates of adverse events
were comparable between the denosumab and placebo groups
233 model (a sigmoid curve with variable slope)
were comparable between the early XTT and spectrophotome
234 Mean transit time and blood volume fraction
were comparable between the four groups of rats.
235 Hemoglobin levels
were comparable between the groups.
236 along with 3-year patient and graft survival
were comparable between the groups.
237 Baseline characteristics
were comparable between the groups.
238 Although all the mucoinflammatory features
were comparable between the immunocompetent Tg(+) and Ra
239 Pneumonia rates
were comparable between the intervention (24.6%) and con
240 nation rates, although not protocol defined,
were comparable between the intervention and comparison
241 ry attenuation values +/- standard deviation
were comparable between the iodixanol 270 and iopromide
242 turbances (5% v 0%), grade 3 to 4 toxicities
were comparable between the IROX and irinotecan groups,
243 Safety and reproducibility
were comparable between the methods of allergen applicat
244 trends and patterns of biological responses
were comparable between the multi-cellular models we pro
245 Other safety measures
were comparable between the olanzapine plus samidorphan
246 onths on study, vision and anatomic outcomes
were comparable between the PDS 100-mg/ml and monthly in
247 erm survival and freedom from reintervention
were comparable between the Ross procedure and mechanica
248 activity and physical function improvements
were comparable between the SC and IV abatacept-treated
249 discontinuation rates due to adverse events
were comparable between the tasimelteon (3 [6%] of 52 pa
250 Types and rates of adverse events
were comparable between the treatment groups.
251 Baseline characteristics
were comparable between the treatment-naive and treatmen
252 Grade 3/4 toxicities
were comparable between the two arms except that grade 3
253 sponse improvement, and duration of response
were comparable between the two arms.
254 Adverse events
were comparable between the two central venous catheter
255 ts revealed that accuracy and reaction times
were comparable between the two conditions, suggesting t
256 ng primers specific to this internal control
were comparable between the two devices, indicating negl
257 binding of both benzphetamine and efavirenz
were comparable between the two enzymes.
258 rius and F4/80 immunostaining, respectively,
were comparable between the two groups of mice.
259 ty of Thoracic Surgeons risk score and eGFR,
were comparable between the two groups.
260 %; non-CACPR: 96.9.9%, 88.7%, 80.0%; P = .4)
were comparable between the two groups.
261 Baseline characteristics
were comparable between the two groups.
262 d 3-year patient survival and renal function
were comparable between the two groups.
263 umbers of resident alveolar macrophages (AM)
were comparable between the two groups.
264 characteristics and the underlying anomalies
were comparable between the two groups.
265 Although overall prevalence rates
were comparable between the two methods, results varied
266 neurologists reported that all rsEEG traces
were comparable between the wet and dry electrode headse
267 The taxonomic richness and Shannon index
were comparable between the WM and MDM but were signific
268 mph nodes and the antibody response in serum
were comparable between the WT and KO animals.
269 ms, comorbidities, and durations of symptoms
were comparable between time intervals.
270 isms, comorbidities and duration of symptoms
were comparable between time-intervals.
271 ers, whereas levels of endogenous mouse CCN2
were comparable between transgenic and wild-type mice.
272 Illness-related anxiety
was comparable between treatment arms at all time points
273 FSR/HFS; 90% v 66%); grade 3 to 4 toxicities
were comparable between treatment arms except HFSR/HFS (
274 Other adverse events
were comparable between treatment groups.
275 Adverse events
were comparable between treatment groups.
276 ontrolled trial, yet the time to pre-syncope
was comparable between trials (544 +/- 130 vs. 572 +/- 1
277 we show that the frequency of recombination
is comparable between Trypanosoma congolense and Trypano
278 capsules, although the normoglycemic period
was comparable between two groups of rats receiving tran
279 terrater reliability of handheld dynamometry
was comparable between two studies (intraclass correlati
280 ar filtration rates after 1 year and 5 years
were comparable between uDCD and cDCD (1 year: uDCD, 44.
281 Antibody responses
were comparable between uninfected and HIV-infected popu
282 arison to controls; by 24 hours, drug uptake
was comparable between untreated and BAPTA-treated hair
283 ination (key depression treatment indicators
were comparable between usual care participants managed
284 he effect on cellular immunity, Ab responses
were comparable between vaccinated wild-type and IL-33-d
285 us-specific cytotoxic-T-lymphocyte responses
were comparable between vaccine groups.
286 , mortality rates and LV functional recovery
were comparable between valve replacement techniques.
287 ng by each region, normalized lesion volumes
were comparable between white and grey matter in primary
288 Although thymic cellularity
was comparable between wild type (WT) and DKO mice, CD3(
289 significant elevation in blood pressure that
was comparable between wild-type and CXCL16 knockout mic
290 pression of endogenous LCMV-specific T cells
was comparable between wild-type and DeltaDC mice during
291 ogold labeling for GluN2A at MF-CA3 synapses
was comparable between wild-type and Neto-null mice, lab
292 growth factor (VEGF) in response to ischemia
was comparable between wild-type and Notch mutant mice,
293 However, cardiac FAO rates
were comparable between wild-type and ACC-DKI mice at ba
294 ription activity and p53 protein degradation
were comparable between wild-type and p50-/- cells.
295 AS severity
was comparable between women and men (peak aortic jet ve
296 Bcl-2 or Bcl-XL, because expression of these
was comparable between WT and double knockout OTII cells
297 covery of dietary FA in the intestinal lumen
was comparable between WT and KO, consistent with the su
298 he staphylococcal superantigen enterotoxin B
were comparable between WT and DKO mice.
299 Levels of impairment
are comparable between youths with bipolar disorder and
300 Adverse events
were comparable between zirconium cyclosilicate and plac